Post

New research · Ophthalmology
Retina (Philadelphia, Pa.) · 3d
Randomized trialRetina (Philadelphia, Pa.) · 2026

Evaluating the Efficacy and Safety of Topical Difluprednate in Patients with Chronic Central Serous Chorioretinopathy.

Parul Yadav, Shakha, Sanjay Mishra … Rajpal Vohra
Read paper
OphthalmologyRandomized trial

Topical difluprednate led to complete subretinal fluid resolution far more often than observation.

Evaluating the Efficacy and Safety of Topical Difluprednate in Patients with Chronic Central Serous Chorioretinopathy.

Parul Yadav … Rajpal Vohra
Retina (Philadelphia, Pa.) · 2026
Purpose

To evaluate the efficacy and safety of topical Difluprednate ophthalmic emulsion 0.05% in chronic Central Serous Chorioretinopathy (cCSCR) and compare its outcomes with oral eplerenone and observation.

Methods

This pilot open-label randomised controlled trial included patients with cCSCR of ≥3 months' duration or relapsing cases with subfoveal or juxtafoveal leakage on angiography.

n = 53 adults
Results

difluprednate cleared retinal fluid completely in most patients, far outperforming no treatment

90%
Difluprednate
45%
Eplerenone
23%
Observation
More results

The difluprednate group showed significantly greater reductions in subfoveal choroidal thickness (subfoveal choroidal thickness) and improvements in 3-mm microperimetry thresholds compared with the observation group (p = 0.012 and p = 0.022, respectively).

More results

It also demonstrated the largest decrease in central macular thickness, although this was not statistically significant (p = 0.19).

Ocular hypertension developed in 30% of difluprednate-treated eyes and was controlled with topical antiglaucoma medication.

“
Conclusion · 1 of 2

Topical difluprednate produced superior anatomical and functional improvements in SRF resolution, subfoveal choroidal thickness reduction, and retinal sensitivity within 3-mm when compared with oral eplerenone and observation.

Conclusion · 2 of 2

Thus, with a manageable safety profile, it may serve as an effective therapeutic option for cCSCR.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
92.3%
most laser-treated eyes had a favorable eye-structure outcome
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
50%
older patients were more likely to lose three or more lines of vision
Study
81%
trials where mask air leaks were detected blowing toward the eyes
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Study
379 +/- 156 microm
lower thickness in the central retina, checked with an eye scan
Case Report
9 of 10 eyes
eyes had better measured vision after treatment